DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
1.340
+0.070 (5.51%)
At close: Mar 27, 2024, 4:00 PM
1.330
-0.010 (-0.75%)
Pre-market: Mar 28, 2024, 4:39 AM EDT
5.51%
Market Cap 39.97M
Revenue (ttm) 9.19M
Net Income (ttm) -36.65M
Shares Out 29.83M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 188,734
Open 1.270
Previous Close 1.270
Day's Range 1.250 - 1.340
52-Week Range 0.470 - 7.460
Beta 0.82
Analysts Hold
Price Target 41.00 (+2,959.7%)
Earnings Date Mar 27, 2024

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-a... [Read more]

Sector Healthcare
IPO Date Sep 28, 2000
Employees 72
Stock Exchange NASDAQ
Ticker Symbol DRRX
Full Company Profile

Financial Performance

In 2022, DURECT's revenue was $19.28 million, an increase of 37.96% compared to the previous year's $13.98 million. Losses were -$35.33 million, -2.57% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DRRX stock is "Hold." The 12-month stock price forecast is $41.0, which is an increase of 2,959.70% from the latest price.

Price Target
$41.0
(2,959.70% upside)
Analyst Consensus: Hold
Stock Forecasts

News

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.

13 hours ago - PRNewsWire

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatme...

7 days ago - PRNewsWire

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly m...

23 days ago - PRNewsWire

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

7 weeks ago - PRNewsWire

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AADIKTRA
3 months ago - Benzinga

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

-  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET -  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortalit...

4 months ago - PRNewsWire

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment...

4 months ago - PRNewsWire

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg d...

5 months ago - PRNewsWire

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering th...

7 months ago - PRNewsWire

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver disease...

7 months ago - PRNewsWire

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

-    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET -    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif.

8 months ago - PRNewsWire

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases...

8 months ago - PRNewsWire

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...

8 months ago - PRNewsWire

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Topline data anticipated in Q4 2023 CUPERTINO, Calif. , June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of...

10 months ago - PRNewsWire

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif.

11 months ago - PRNewsWire

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the mar...

11 months ago - PRNewsWire

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New Y...

11 months ago - PRNewsWire

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Man...

1 year ago - PRNewsWire

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study

1 year ago - PRNewsWire

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

CUPERTINO, Calif. , March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.

1 year ago - PRNewsWire

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

CUPERTINO, Calif. , March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participa...

1 year ago - PRNewsWire

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

-  Webcast of Earnings Call Today, March 7 th at 4:30 p.m. ET -  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif.

1 year ago - PRNewsWire

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

CUPERTINO, Calif. , Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference ca...

1 year ago - PRNewsWire

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

CUPERTINO, Calif. , Feb. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of a...

1 year ago - PRNewsWire

DURECT Announces 1-for-10 Reverse Stock Split

CUPERTINO, Calif. , Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ in...

1 year ago - PRNewsWire